Several studies have attempted to avoid an increase in VEGF while employing GnRH agonists to induce ovulation [6, 7]; however, this strategy does not totally avoid OHSS onset [8], leaving a need for treatments that block VEGF/VEGF receptor 2 (VEGFR2) signaling completely. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.